Roivant Sciences

Roivant is a biopharmaceutical holding company headquartered in New York. The company owns subsidiaries that develop and manufacture drugs in the areas of immunology, dermatology, hematology, neurology, oncology, and infectious and respiratory diseases. Roivant also conducts research of gene, RNA and silicon therapeutics, protein degraders, and provides Big Data and AI services for the healthcare industry. For drug discovery, Roivant employs in silico drug design and machine learning modeling. In China, the company runs a cellular therapeutics programme and already has 3 drugs for treatment of different diseases in the pipeline. In total, Roivant's subsidiaries have 17 drugs in the pipeline, with development stages ranging from preclinical to phase 3 clinical trials.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price


SoftBank Vision FundSoftBank Vision Fund
Founders FundFounders Fund
Viking Global InvestorsViking Global Investors
QVT FinancialQVT Financial
Dexcel PharmaDexcel Pharma
Novaquest Capital ManagementNovaquest Capital Management
RTW Investments LLCRTW Investments LLC